BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 25370765)

  • 1. [Impact of AR-V7 expression on overall survival for patients with metastatic prostate cancer].
    Qu Y; Ye D; Dai B; Kong Y; Chang K; Gu C; Sun Z; Zhang H; Zhu Y; Shi G
    Zhonghua Wai Ke Za Zhi; 2014 Aug; 52(8):622-6. PubMed ID: 25370765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression.
    Zhao H; Coram MA; Nolley R; Reese SW; Young SR; Peehl DM
    J Urol; 2012 Dec; 188(6):2158-64. PubMed ID: 23088973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
    Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
    Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
    Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
    Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
    Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D; Sültmann H; Duensing A; Perner S; Cronauer MV; Stephan C; Debus J; Schrader AJ; Kristiansen G; Hohenfellner M; Duensing S
    Urol Oncol; 2018 Apr; 36(4):161.e19-161.e30. PubMed ID: 29198908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Orsola A; Planas J; Catalán R; Reventós J
    Int J Biol Markers; 2005; 20(4):209-16. PubMed ID: 16398402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients.
    Li H; Wang Z; Xiao W; Yan L; Guan W; Hu Z; Wu L; Huang Q; Wang J; Xu H; Zhang X; Ye Z
    Mod Pathol; 2018 Jan; 31(1):198-208. PubMed ID: 29076496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
    Liu RJ; Hu Q; Li SY; Mao WP; Xu B; Chen M
    Technol Cancer Res Treat; 2021; 20():15330338211035260. PubMed ID: 34313171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.
    Kim KH; Han KS; Kim KH; Kim DK; Koo KC; Rha KH; Choi YD; Hong SJ
    Urol Oncol; 2015 Sep; 33(9):383.e17-22. PubMed ID: 26004165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of androgen independence in metastatic prostate cancer.
    Sim HG; Lau WK; Cheng CW
    BJU Int; 2004 Jun; 93(9):1221-4. PubMed ID: 15180610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
    García JL; Lozano R; Misiewicz-Krzeminska I; Fernández-Mateos J; Krzeminski P; Alfonso S; Marcos RA; García R; Gómez-Veiga F; Virseda Á; Herrero M; Olmos D; Cruz-Hernández JJ
    Clin Transl Oncol; 2017 Nov; 19(11):1350-1357. PubMed ID: 28600675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
    Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
    Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer.
    Qu Y; Dai B; Ye D; Kong Y; Chang K; Jia Z; Yang X; Zhang H; Zhu Y; Shi G
    Sci Rep; 2015 Jan; 5():7654. PubMed ID: 25563505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors affecting progression and survival in metastatic prostate cancer.
    Nayyar R; Sharma N; Gupta NP
    Urol Int; 2010; 84(2):159-63. PubMed ID: 20215819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
    Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT
    Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy.
    Li H; Zhang Y; Li D; Ma X; Xu K; Ding B; Li H; Wang Z; Ouyang W; Long G; Zeng J; Liu H; Yan L; Zhang Y; Liu Z; Guan W; Hu Z; Liu C; Wan J; Wang G; Pu X; Zhang M; Guo L; An R; Qi J; Guo A; Ye Z; Liu J; Zhang X; Xu H
    Eur Urol; 2021 Jun; 79(6):879-886. PubMed ID: 33579577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer.
    Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
    BMC Urol; 2014 Apr; 14():33. PubMed ID: 24773608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.